Efficacy

Kisqali (Ribociclib) Efficacy in Breast Cancer

Kisqali (ribociclib) is a prescription medication that is used for the treatment of certain types of breast cancer. Specifically, it is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Ribociclib is often used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in premenopausal women in conjunction with ovarian suppression. The efficacy of Kisqali was demonstrated in several clinical trials, including the MONALEESA trials, which showed a significant improvement in progression-free survival when ribociclib was added to letrozole or fulvestrant compared to the use of these endocrine therapies alone.

In the MONALEESA-2 trial, for example, the combination of ribociclib and letrozole significantly extended progression-free survival compared to placebo plus letrozole in postmenopausal women with HR+/HER2- advanced breast cancer. The trial results indicated that patients receiving the combination therapy had a 44% lower risk of disease progression or death. These findings have established ribociclib as a valuable treatment option in the management of HR+/HER2- advanced breast cancer, offering patients a chance to control the disease for a longer period.

Trodelvy (Sacituzumab Govitecan-hziy) Efficacy in Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) is another medication used in the treatment of breast cancer, specifically for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Sacituzumab govitecan-hziy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate, which means it works by delivering a chemotherapy drug directly to the cancer cells. The efficacy of Trodelvy was evaluated in a study known as the ASCENT trial, which demonstrated a significant improvement in overall survival and progression-free survival for patients treated with sacituzumab govitecan-hziy compared to those who received standard chemotherapy.

In the ASCENT trial, patients receiving Trodelvy had a median overall survival of 12.1 months compared to 6.7 months for patients on chemotherapy, representing a 52% reduction in the risk of death. Moreover, the median progression-free survival was 5.6 months for patients treated with Trodelvy, compared to 1.7 months for those on chemotherapy. These results highlight the potential of Trodelvy to offer a meaningful clinical benefit in a patient population with a historically poor prognosis and limited treatment options. Trodelvy has thus become an important therapeutic option for patients with previously treated metastatic TNBC.